ClinicalTrials.gg
CompletedNCT01192399Updated Mar 13, 2018Results posted

Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

A Phase 2 interventional study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Alexion Pharmaceuticals, Inc.. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-03-13.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.

Enrollment
11th of 18
29 · median 37
Started
2007
the only one that year
Phase 2
2 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
8 of 18
Alexion Pharmaceuticals, Inc.

Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 11th largest by enrollment, is the only one that started in 2007, is one of 2 in phase 2, and was the 7th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →

About eculizumab

eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal as a file.
02

Study summary

A study to assess the safety and efficacy of eculizumab in Japanese patients with hemolytic PNH.

Read the detailed description

The objective of this study was to assess the safety and efficacy of eculizumab in Japanese patients with hemolytic PNH. In addition, the pharmacokinetics (PK) and pharmacodynamics (PD) of eculizumab in Japanese patients were assessed and compared to that of non-Japanese patients who had participated earlier studies of eculizumab treatment in hemolytic PNH.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • Hemolytic Paroxysmal Nocturnal Hemoglobinuria
  • Eculizumab
  • PNH
  • Japan
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese individuals at least 12 years of age
  • Diagnosis of PNH > 6 months
  • At least one transfusion in the past 2 years for anemia or anemia-related symptoms
  • LDH level ≥ 1.5 x within 12 weeks
  • Presence of a glycosylphosphatidylinositol (GPI)-deficient red blood cell (RBC) clone (type III cells) by flow cytometry of ≥10%
  • Negative serum pregnancy test for women of

Exclusion criteria

Exclusion Criteria:

  • count \< 30,000/µL
  • ≤ 500/µL
  • Known or suspected hereditary complement deficiency
  • History of hematopoietic stem cell transplant
  • History of meningococcal disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Eculizumab

    Eculizumab intravenous infusions every week x 4 doses, then 900 mg 1 week later for 1 dose, then 900 mg every 2 weeks for 4 doses

    Biological: Eculizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Lactate Dehydrogenase

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Total Score

    The FACIT-Fatigue scale, Version 4.0, is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.

    Time frame: Baseline, Week 12

  2. Change From Baseline in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Count

    Time frame: Baseline, Week 12

  3. Number of Units of Packed Red Blood Cells (pRBCs) Transfused

    Comparison of number of units of pRBCs transfused in the 12 weeks prior to the first dose of eculizumab, and between baseline and 12 weeks after the first dose of eculizumab

    Time frame: 12 weeks pre-treatment, baseline, 12 weeks post-treatment

  4. Change From Baseline in Lactate Dehydrogenase (LDH) Area Under the Curve (AUC)

    Time frame: Baseline to Week 12

  5. Change From Baseline in Plasma Free Hemoglobin

    Time frame: Baseline, Week 12

  6. Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Score (Global Health Status)

    The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. For global health status, a high score represents a high quality of life.

    Time frame: Baseline, Week 12

07

Results

Posted Mar 13, 2018

Participant flow

Participant flow — Overall Study
MilestoneEculizumab
Started29
Completed27
Not completed2
Withdrew: Lack of efficacy2

Outcome measures

PrimaryChange From Baseline in Lactate Dehydrogenase
Time frame:
Baseline, Week 12
Reported as:
Mean · Units/Liter
Change From Baseline in Lactate Dehydrogenase
Units/LiterEculizumab
Baseline1845.1 ± 115.34
Week 12398.7 ± 99.15
Change from Baseline at Week 12-1446.4 ± 138.68
Statistical analysis
  • Eculizumab · Sign test · p = <0.0001
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Total Score

The FACIT-Fatigue scale, Version 4.0, is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Total Score
units on a scaleEculizumab
Baseline38.5 ± 1.88
Change from Baseline at Week 124.1 ± 2.25
SecondaryChange From Baseline in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Count
Time frame:
Baseline, Week 12
Reported as:
Mean · cells x 10^12/L
Change From Baseline in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Count
cells x 10^12/LEculizumab
Baseline1.3 ± 0.14
Week 121.8 ± 0.19
Change from Baseline at Week 120.5 ± 0.10
SecondaryNumber of Units of Packed Red Blood Cells (pRBCs) Transfused

Comparison of number of units of pRBCs transfused in the 12 weeks prior to the first dose of eculizumab, and between baseline and 12 weeks after the first dose of eculizumab

Time frame:
12 weeks pre-treatment, baseline, 12 weeks post-treatment
Reported as:
Mean · Units
Number of Units of Packed Red Blood Cells (pRBCs) Transfused
UnitsEculizumab
12 Weeks Pre-Dose5.2 ± 1.04
12 Weeks Post-Dose1.5 ± 0.67
Difference Post - Pre-3.7 ± 1.12
SecondaryChange From Baseline in Lactate Dehydrogenase (LDH) Area Under the Curve (AUC)
Time frame:
Baseline to Week 12
Reported as:
Mean · U/L x Day
Change From Baseline in Lactate Dehydrogenase (LDH) Area Under the Curve (AUC)
U/L x DayEculizumab
Change From Baseline in Lactate Dehydrogenase (LDH) Area Under the Curve (AUC)-113540.5 ± 10539.33
SecondaryChange From Baseline in Plasma Free Hemoglobin
Time frame:
Baseline, Week 12
Reported as:
Mean · mg/dL
Change From Baseline in Plasma Free Hemoglobin
mg/dLEculizumab
Baseline22.6 ± 2.61
Change from Baseline at Week 12-19.8 ± 2.71
SecondaryChange From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Score (Global Health Status)

The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. For global health status, a high score represents a high quality of life.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Score (Global Health Status)
units on a scaleEculizumab
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Score (Global Health Status)8.9 ± 6.39

Adverse events

Collected over Adverse events were collected over the full study period (12 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab0/29 (0%)1/29 (3.4%)28/29 (96.6%)
Most frequent serious events
Most frequent serious events
EventEculizumab
PyrexiaGeneral disorders1/29
C-Reactive Protein IncreasedInvestigations1/29
Most frequent other events
Showing 10 of 16
Most frequent other events
EventEculizumab
HeadacheNervous system disorders15/29
NasopharyngitisInfections and infestations12/29
NauseaGastrointestinal disorders6/29
DiarrhoeaGastrointestinal disorders4/29
VomitingGastrointestinal disorders3/29
EczemaSkin and subcutaneous tissue disorders3/29
AnaemiaBlood and lymphatic system disorders2/29
LeukopeniaBlood and lymphatic system disorders2/29
TinnitisEar and labyrinth disorders2/29
Conjunctival haemorrhageEye disorders2/29

Baseline characteristics

Age, Continuous
Age, Continuous(years)Eculizumab
Mean47.0 ± 12.39
Sex: Female, Male
Sex: Female, Male(Participants)Eculizumab
Female15
Male14
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eculizumab
Japanese29
Region of Enrollment
Region of Enrollment(Participants)Eculizumab
Japan29
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011 Jan;93(1):36-46. doi: 10.1007/s12185-010-0748-9. Epub 2011 Jan 12. PubMed 21222185 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2018, 9 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2010
First posted
Sep 1, 2010
Start
Nov 2007
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Mar 13, 2018
Last update
Mar 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01192399
Responsible party
Sponsor
First posted
Sep 1, 2010
Start date
Nov 2007
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Mar 13, 2018
Last update
Mar 13, 2018

Study contacts

Stephen Squinto, PhD
study director · Alexion Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion